Intraluminal versus infiltrating gallbladder carcinoma: Clinical presentation, ultrasound and computed tomography

Table 1 Clinical and pathological data from 37 patients with GBCA presented as intraluminal mass, and 28 patients with GBCA presented as infiltrating tumor (mean ± SD) n (%)

	Intraluminal mass	Infiltrating tumor	P value
Age (yr)2	65.49 ± 1.51	73.07 ± 1.90	0.020a
Sex ratio (female)1	23 (62.1)	18 (64.3)	0.861
RUQ or epigastric pain or discomfort1	28 (75.7)	23 (82.1)	0.530
Jaundice1	3 (8.1)	13 (46.4)	< 0.001a
Fever1	3 (8.1)	10 (35.7)	0.006a
Incidental finding	7 (18.9)	3 (8.1)	0.364
Aspartate aminotransferase (IU/L)2	89.36 ± 101.14	74.37 ± 88.62	0.914
Alanine aminotransferase (IU/L)2	113.21 ± 103.97	78.87 ± 82.04	0.252
Alkaline phosphatase (IU/L)2	119.36 ± 87.80	220.68 ± 164.84	0.030a
Total bilirubin (mg/dL)2	1.74 ± 2.87	3.50 ± 3.51	0.011a
Presence of gallstones1	12 (32.4)	22 (78.6)	< 0.001a
Gallbladder size
Length (cm)2	7.47 ± 1.70	6.47 ± 1.83	0.032a
Width (cm)2	4.21 ± 1.43	2.67 ± 0.93	0.026a
T1 tumor1	8 (21.7)	1 (3.6)	0.038a
T2 tumor1	11(29.7)	9 (32.1)	0.835
T3 tumor1	17 (45.9)	16 (57.1)	0.267
T4 tumor1	1 (2.7)	2 (7.2)	0.581
Metastatic lymph nodes1	13 (35.1)	15 (53.6)	0.712
Survival < 12 mo1	16 (43)	18 (68)	0.017a

¹Fisher's exact test or χ² test;

²Wilcoxon rank sum test;

^aSignificant at 0.05; RUQ: Right upper quadrant; GBCA: Gallbladder carcinoma.